Bingnan Gu, PhD, MBA, Senior Director, R&D, Viral Vector and Cell Therapy and Vijetha Bhat, Cell & Gene Technical Expert, Licensing, Lonza
Over the past decade, gene therapy has emerged as one of the most promising therapeutic modalities. Yet, unlocking its full potential depends on overcoming a central challenge: how to manufacture viral vectors at scale, consistently, and cost-effectively. Lonza recognized this challenge early and committed to developing a next-generation adeno-associated virus (AAV) producer cell line platform. When we look back on the past ten years, what stands out is not a single breakthrough moment, but a journey defined by persistence, learning, and collaboration.
Many colleagues have been part of this effort at different stages, but with a shared goal: to develop a robust AAV producer cell line platform that could help address one of the central challenges in gene therapy. The journey began in 2016, when early work focused on a CHO-based system. At the time, it seemed like an exciting direction. However, by 2018, it became clear that this path would not deliver the performance needed. Making the decision to stop and pivot was not easy, but it was necessary. We transitioned to a HEK293-based approach, which opened new possibilities but also introduced a fresh set of challenges.
Learning Through Setbacks and Scientific Iteration
From there, progress was steady but rarely straightforward. AAV biology is inherently complex. Achieving high productivity while maintaining cell health requires careful balance, particularly given the toxic effects associated with some viral components. One of our key focuses became the design of inducible systems – a way to tightly control when and how the cells produce AAV. Early proof-of-concept work gave us confidence, but translating that into a stable, high-performing system took years of iteration.
We also learned that solving these challenges required more than internal effort alone. Over time, we collaborated with our broader expert teams at Lonza as well as engaging with external experts and explored multiple approaches across the field. Not all of them worked. Some collaborations ended without success, and some industry developments showed us what not to pursue. But each experience sharpened our understanding and helped guide our next steps.
Turning Progress Into a Scalable Solution
Around 2022, we began to see real momentum. Improved vector designs and better control of gene expression translated into measurable gains. We started to generate cell pools and clones with promising productivity. By 2023, we reached an important milestone: clonal cell lines delivering titers above 1×10¹² viral genomes per milliliter, with stable performance across multiple passages.
For us, this was not just a technical achievement; it was a confirmation that the concept could work at the level required for real-world manufacturing applications. Importantly, these results were not limited to small-scale experiments. The system showed consistent performance as we scaled from mini-bioreactors to larger formats, reinforcing its practical relevance.
Delivering Impact Through Integrated Expertise
What makes this platform meaningful is how it changes the manufacturing model. By building all the necessary components directly into the cell line, we remove the need for repeated transient transfection. This simplifies operations, reduces dependence on plasmid supply, improves consistency from batch to batch, and significantly reduces the overall cost of goods for production. For those working in gene therapy development, these are not small improvements; they are transformative advances that bring broader patient access within reach.
Looking back, one of the most important factors in this journey has been the collective expertise across Lonza. This work brought together scientists and engineers with backgrounds in cell biology, vector design, process development, and manufacturing. That combination allowed us to think beyond individual experiments and design a platform that could perform in real-world settings.
More recently, early partner studies using clinically relevant vector configurations have shown encouraging results, including significant improvements in productivity compared with traditional approaches, while maintaining product quality. These outcomes reinforce why we started this journey in the first place.
This experience has highlighted an important truth: innovation in cell and gene therapy takes time. It requires resilience, openness to change, and a willingness to learn from setbacks.
We are proud of how far this program has come. As we continue to refine and expand this platform, we remain focused on the same goal that has guided us from the beginning: helping to create scalable, reliable manufacturing so that more patients can benefit from gene therapies.
